Tensha Therapeutics

Tensha is staking a claim on drugging bromodomains as an innovative epigenetic approach to novel anti-cancer agents.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rohn, J. Tensha Therapeutics. Nat Biotechnol 30, 305 (2012). https://doi.org/10.1038/nbt0412-305

Download citation

Further reading